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Although important strides have been made in targeted therapy for certain leukemias and subtypes of breast cancer, the
standard of care for most carcinomas still involves chemotherapy, radiotherapy, surgery, or a combination of these. Two
processes serve as obstacles to the successful treatment of carcinomas. First, a majority of deaths from these types of cancers
occurs as a result of distant metastases and not the primary tumors themselves. Second, subsets of cells that are able to survive
conventional therapy drive the aggressive relapse of the tumors, often in forms that are resistant to treatment. A frequently
observed feature of malignant carcinomas is the loss of epithelial traits and the gain of certain mesenchymal ones that are
programmed by the cell-biological program termed the epithelial-to-mesenchymal transition (EMT). The EMT program can
confer (i) an ability to disseminate, (ii) an ability to become stem-like tumor-initiating cells, (iii) an ability to found new tumor
colonies at distant anatomical sites, and (iv) an elevated resistance to therapy. These multiple powers of the EMT program
explain why it has become an attractive target for therapeutic intervention. Recent work has revealed the variable nature of the
EMT, with multiple versions of the program being observed depending on the tissue context and the stage of tumor progres-
sion. In this review, we attempt to crystallize emerging concepts in the research on EMT and stemness and discuss the benefits
of using a differentiation-based therapeutic strategy for the eradication of stem-like populations that have adopted various
versions of the EMT program.
The epithelial-to-mesenchymal transition (EMT) is a
cell-biological program that is important in various as-
pects of development, wound healing, maintenance of
stemness, and tumor progression. Initial observations of
the loss of epithelial properties and the concomitant gain
of mesenchymal traits were made in the laboratory of
Elizabeth Hay, who studied the development of cornea,
limb, notochord, and lens epithelia (Greenburg and Hay
1982). These findings have opened an entire field of re-
search, which associates EMT programs with a multitude
of distinct pathophysiologic processes, including the
malignant progression and metastatic dissemination of
carcinomas. The transition involves a highly coordinated
program whereby epithelial cells loose their characteris-
tics of apical–basal polarity, cell–cell junctions and ad-
herence to the basement membrane and gain, among
other traits, certain properties of mesenchymal cells that
enable them to migrate and invade. The EMT is known to
occur in various different biological contexts, which has
led to its classification into three different types (Kalluri
andWeinberg 2009). A type I EMT refers to the transition
that takes place in the context of development, including
processes that give rise to the mesoderm and primary
mesenchyme from the primitive streak during gastrula-
tion, as well as those that give rise to the migratory neural
crest cells. The type II EMT is utilized during process of
tissue regeneration, such as transient fibrosis and wound
healing. The version of EMT highlighted in the present
discussion is the type III EMT, which is associated with
tumor progression.
EMT IN TUMOR PROGRESSION
Over the past decade, the importance of the EMT pro-
gram in tumor progression has been established by hun-
dreds of studies in awide variety of carcinomas, including
breast, ovarian, pancreatic, prostate, colorectal, and renal
types. The role of the EMT in tumor progression has
been comprehensively reviewed elsewhere (De Craene
and Berx 2013; Tsai and Yang 2013; Nieto et al. 2016)
and is not the major focus of the present review. Briefly,
the acquisition of mesenchymal traits through induction
of an EMT program is thought to enable carcinoma cells
to complete many of the steps of the invasion-metastasis
cascade—the sequence of steps that begins with the local
invasiveness of the neoplastic cells within primary
tumors, their intravasation, translocation through the
circulation, extravasation into the parenchyma of distant
tissues, the founding of micrometastatic deposits, and the
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outgrowth of these deposits into macroscopic metasta-
ses—the last step being termed “colonization” (Fidler
2003; Yang et al. 2004). Expression of the EMT is main-
tained during the early and intermediate stages of the cas-
cade, including invasion through tissue around the
primary tumor, intravasation, transportation as circulating
tumor cells (CTCs) in the vasculature (Yu et al. 2013), and
extravasation following their vascular journey (Labelle
et al. 2011). Following extravasation, disseminated tumor
cells may undergo the reverse of the EMT, termed the
mesenchymal-to-epithelial transition (MET) and thereby
regain the epithelial traits exhibited by their progenitors
within the primary tumor (MET) (Ocana et al. 2012; Tsai
et al. 2012); this last step appears to be critical to allow
metastatic colonization to proceed efficiently.
ALTERNATIVE VERSIONS OF TUMOR
CELL DISSEMINATION
Several reports now show that the escape of carcinoma
cells from primary tumors, as enabled by an EMT pro-
gram, can occur by other mechanisms besides the fre-
quently studied single-cell dissemination. In particular,
the process of collective invasion has been widely report-
ed and occurs when cohorts of cells that held together by
cell–cell junctions advance through the extracellular ma-
trix (Friedl and Gilmour 2009; Friedl et al. 2012). In fact,
three-dimensional reconstruction studies of tumors have
shown that single cell dissemination is, by contrast, rela-
tively rare, with cell clusters being the prevalent agents
of invasion (Bronsert et al. 2014). The polyclonal nature
of certain metastatic colonies is consistent with their
having arisen through collective dissemination of tumor
cell clusters (Cheung et al. 2016), rather than from dis-
seminated single cells, which would ostensibly give rise
to monoclonal metastatic colonies. The expression of
E-cadherin—a key marker of the epithelial cell state—
throughout the bulk of these invasive masses has led
some to question the involvement of EMT in the process
of carcinoma invasiveness. However, certain lines of
evidence indicate that the cells at the leading edges of
invasive cohorts express certain EMT characteristics
(Revenu and Gilmour 2009; Westcott et al. 2015; Ye
et al. 2015). At present, it has not yet been demonstrated
directly that the EMT characteristics expressed by these
leader cells, including notably the trait of invasiveness,
are critical to the forward migration of the cohorts as a
whole.
Additionally, two recent studies using lineage-tracing
studies in mouse models of breast and pancreatic cancer
have questioned the essential role of the EMT program
in the process of metastasis (Fischer et al. 2015; Zheng
et al. 2015). Fischer et al. used Fsp1 as a lineage-tracing
marker of cells that have undergone an EMT and found
that large numbers of Fsp1-negative cells formed metas-
tases in the lung. These results were interpreted as EMT
not having been expressed, even transiently, for the for-
mation of metastases. Although Fsp1 is expressed in cer-
tain versions of the EMT program (e.g., in renal tubular
cells [Okada et al. 1997]), it cannot be used as a reliable
marker of activation of an EMT program, especially in
the absence of convincing data proving that Fsp1 is actu-
ally expressed in a majority of cells undergoing an EMT.
A second paper utilized a lineage-traced mouse model of
pancreatic ductal adenocarcinoma (PDAC), which exhib-
ited a significant reduction in the percentage of a-smooth
muscle actin (aSMA)-expressing cells relative to tumors
with an intact Twist locus (Zheng et al. 2015). As de-
scribed above, use of aSMA expression as a reliable
marker of EMT is complicated by the fact that it is rarely
induced spontaneously upon activation of EMT during
the course of tumor development (Aiello NM and Stanger
BZ, unpubl.) in this particular mouse tumor model, un-
dermining the conclusions presented in this report. To
summarize, we believe that neither of these papers proved
that the EMT did not occur in the metastasizing carcino-
ma cells, leaving intact the notion that the EMT is indeed
necessary for the metastatic dissemination of carcinoma
cells. However, these two reports highlight the fact that
the EMT is not a single, stereotypical program, and that
various versions of this program are expressed under
different conditions in a variety of carcinomas. This por-
trayal of multiple versions of the EMT program will be
discussed further below.
EMT AND STEMNESS
Since the initial discovery of the connection between
breast carcinomas that have undergone an EMT and the
entrance into a stem-like state (Mani et al. 2008; Morel
et al. 2008), a number of studies have extended these
findings to report similarly the acquisition of stemness
following the EMT in multiple tumor types, including
colorectal (Fan et al. 2012), ovarian (Long et al. 2015),
pancreatic (Rasheed et al. 2010), prostate (Kong et al.
2010), and renal (Zhou et al. 2016), among other types
of carcinomas. Additionally, the EMT program has also
been shown to be important for the normal mammary
epithelial stem cell state (Guo et al. 2012; Nassour et al.
2012).
Although the connection between the EMT and acqui-
sition of stem-like properties is now widely accepted, not
all cells that have undergone an EMT exhibit increased
stemness. Thus, several studies have reported the loss of
stem-like properties in carcinomas upon undergoing an
EMT (Celia-Terrassa et al. 2012; Chang et al. 2013; Xie
et al. 2014), indicating that the acquisition of mesenchy-
mal traits is not, on its own, conducive to acquisition of
increased stemness. In more detail, there is increasing
evidence that, rather than operating as a binary switch,
the EMT program generates cells residing in a spectrum
of multiple phenotypic states lying between the fully ep-
ithelial and fully mesenchymal states (Fig. 1), and that
cells that have passed through a complete EMT program
and become entirely mesenchymal actually lack the abil-
ity to function as stem cells, both normal and neoplastic.
Instead, there is growing evidence that a cell that has
only undergone a partial EMT, thereby expressing both
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retained epithelial and acquired mesenchymal traits, is
best positioned to acquire stem-like properties (Grosse-
Wilde et al. 2015; Jolly et al. 2015a,b; Andriani et al.
2016).
COULD THE EMT ENCOMPASS THE INITIAL
LOSS OF EPITHELIAL TRAITS OBSERVED
DURING MALIGNANCY?
In fact, the actions of the EMT program are not limited
to advanced stages of carcinoma progression. Instead,
an EMT can also participate in the disruption of the ep-
ithelial state that is a common feature of early stages of
malignant transformation (Fig. 2). These early steps are
characterized by the loss of polarized organization of
epithelial tissue (Lee and Vasioukhin 2008), a loss of
cell–cell junctions that compromises the barrier function
of epithelial tissue (Martin and Jiang 2009), and the deg-
radation of interactions of epithelial cells with the under-
lying basement membrane (Barsky et al. 1983).
Loss of cell polarity may be the earliest manifestation
of the actions of an EMT program. As an example, the
overexpressed HER2 protein, which functions as a driver
of a significant proportion of breast cancers, disrupts nor-
mal apical–basal epithelial cell polarity by interacting
with components of the Par polarity complex, including
Par6 and aPKC. Inhibition of these interactions deprives
HER2 of its ability to disrupt the acinar organization and
polarity of the mammary epithelium, a key event during
the initial stages of carcinogenesis (Aranda et al. 2006).
Moreover certain proteins that act as tumor suppressors
play important roles in maintaining cell polarity—for
example, PTEN maintaining apical–basal polarity dur-
ing epithelial morphogenesis (Martin-Belmonte et al.
2007) and Par3 curbing tumor progression and metastasis
(McCaffrey et al. 2012; Li et al. 2014).
These reports indicate the importance of maintaining
epithelial polarity as a means of curbing malignancy but
do not address whether EMT programs are activated upon
loss of polarity. In fact, studies have shown that both
the Snail and Zeb family of EMT-inducing transcription
factors (EMT-TFs) are capable of repressing the tran-
scription of key polarity genes. Snail is known to repress
the transcription of Crumbs3, which codes for a key po-
larity factor, while also disrupting the localization of
the Crumbs and Par complexes (Whiteman et al. 2008).
Similarly, Zeb1 also represses transcription of Crumbs3,
while also repressing HUGL2, Lgl2, and PATJ in breast
and colon cancer cells (Aigner et al. 2007; Spaderna et al.
2008). Loss of Zeb1 enabled a partial restoration of
epithelial polarity, demonstrating that the EMT-TFs
could be directly responsible for the loss of this epithelial
trait. Thus, the loss of polarity that is characteristic of the
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Figure 1. Although we have, in the past, thought of the epithelial-to-mesenchymal transition (EMT) program as a binary switch
between two distinct cell states (A), more recent evidence points to the EMT representing a spectrum of different cell states anywhere in
between the extreme epithelial and mesenchymal states depending on the state that the cell was originally residing in and the nature
of the program that manifests. The sequence of events that defines the EMT is still poorly understood—that is, whether (B) the loss of
epithelial traits occurs over multiple steps, with the gain of mesenchymal traits being the final step in the cascade, or if (C ) the loss
of epithelial traits occurs over a relatively short period of time, followed by a stepwise acquisition of mesenchymal properties.
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initial stages of carcinogenesis may represent an early
manifestation of the EMT program.
Similarly, it has been recognized for some time now that
loss of adherens and tight junctions that enable cell–cell
adhesions can prevent the acquisition of invasive proper-
ties of carcinomas (Frixen et al. 1991; Martin and Jiang
2009). Indeed, multiple studies report the importance of
retaining adherens and tight junctions to prevent the ac-
quisition of malignant phenotypes in colorectal (Born-
holdt et al. 2011), pancreatic (Takai et al. 2005), and
breast carcinomas (Vleminckx et al. 1991; Cavallaro
and Christofori 2004; Martin et al. 2010), among others.
Thus, together with cell polarity, cell–cell junctions rep-
resent key traits associated with cells of epithelial tissue
and their architectural organization. These traits are often
lost at the initial stages of malignancy, and in many cases,
must be lost in order for successful malignant transforma-
tion. Here again, it is well documented that the EMT-TFs
play a significant role in the disruption of cell junctions
through the transcriptional repression of CDH1 (Comijn
et al. 2001; Hajra et al. 2002; Bolos et al. 2003; Eger et al.
2005), which codes for the key adherens junction protein
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Figure 2. The epithelial-to-mesenchymal transition (EMT) has traditionally been associated, almost exclusively, with the gain of
mesenchymal properties. More recent evidence indicates that an overt gain of mesenchymal traits may not be required for the stem-like
properties of cells that have undergone an EMT (A). Thus, the ability of the EMT-inducing transcription factors to alter apical–basal
polarity and repress the transcription of genes required to maintain cell–cell junctions may be equally important functions of EMT-
inducing transcription factors (B). Similarly, the role of the EMT-inducing transcriptional factors (EMT-TFs) in inducing the
transcription of genes whose products are known to degrade components of the basement membrane is also key in the initial stages
of the EMT.
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E-cadherin, as well as tight junction proteins such as clau-
dins (Martinez-Estrada et al. 2006) and occludins (Ike-
nouchi et al. 2003; Ohkubo and Ozawa 2004). Through
the repression of these genes, whose products maintain
epithelial cell junctions, the EMT program enables an
initial advance of carcinoma cell progression toward
high-grade malignancy, doing so without the gain of ad-
ditional overt mesenchymal traits.
Another key property of epithelial tissue is the main-
tenance of interactions with the basement membrane,
which provides structural support while also regulating
cell behavior through its ability to control invasion and
thereby maintain tissue integrity (Paulsson 1992; Kelley
et al. 2014). Snail is known to up-regulate the expression
of several matrix metalloproteinase (MMP) genes, in-
cludingMMP9, which degrades the basement membrane
and stimulates tumor cell invasion (Jorda et al. 2005;
Miyoshi et al. 2005; Kessenbrock et al. 2010). Addition-
ally, other factors such as Zeb2 and TGF-b indirectly
activate MMP2 through activation of the Ets-2 transcrip-
tion factor (Taki et al. 2006). Hence, a variety of EMT-
inducing signals are capable of repressing key epithelial
traits that pave the way for malignancy and tumor pro-
gression. Importantly, in none of these cited reports was
the full spectrum of EMT-associated mesenchymal traits
examined, leaving open the possibility that partial EMT
programs, which only involve the loss of certain epithe-
lial traits without gain of a full suite of mesenchymal
ones, were launched.
DOES AN EMT INVARIABLY ENTAIL
THE ACQUISITION OF OVERT
MESENCHYMAL TRAITS?
As suggested above, increasing evidence indicates that
the term EMT subsumes a collection of cell-biological
programs rather than a single, stereotypical one. Initially,
it was believed that cells that have undergone an EMT
resemble fibroblasts (i.e., acquire properties that make
them completely mesenchymal). This prompted various
efforts to induce as complete an EMT program as exper-
imentally possible, this being undertaken with the pre-
conception that the more complete the EMT, the more
aggressive carcinoma cells would appear.
With the passage of time, this thinking has become
more nuanced, and we now realize that the acquisition
of a full range of EMT-induced mesenchymal traits and
associated loss of all epithelial markers is not necessarily
correlated with the acquisition by carcinoma cells of
aggressive traits and, as discussed above, stemness. More-
over, because different carcinoma cell types exhibit dif-
fering proportions of epithelial and mesenchymal traits
(Li and Kang 2016), certain studies have attempted to
classify breast cancer cells by assigning them scores
that would indicate the extent of their EMT-associated
features (Tan et al. 2014). Such studies have highlighted a
by-now widely embraced notion: there is no standard,
stereotypical version of the EMT program. It is therefore
likely that in certain cases, aggressive metastasizing car-
cinomas may exhibit overt mesenchymal properties that
aid its metastatic spread (Trimboli et al. 2008; Bonnomet
et al. 2012), whereas in other cases they may not require
these properties; moreover, display of these traits may
actually be counterproductive for stemness and tumor
progression (Celia-Terrassa et al. 2012).
These various reports converge on the increasingly ac-
cepted notion that advance partially through an EMT
program and resulting residence by carcinoma cells in a
partially epithelial, partially mesenchymal state favors
tumor progression and metastasis (Lundgren et al.
2009; Jordan et al. 2011; Bednarz-Knoll et al. 2012;
Sampson et al. 2014; Grosse-Wilde et al. 2015; Hong
et al. 2015; Schliekelman et al. 2015). This suggests, in
turn, than an acquisition of overt mesenchymal traits may
not be necessary for carcinoma cells to develop aggres-
sive, metastatic properties. Given the prevalence of pro-
cesses such as collective migration/invasion by tumor
cell clusters, as discussed earlier, it is likely that the par-
tial EMT state, which enables some cells to transiently
repress certain epithelial properties, is a driving factor for
this form of dissemination (Grigore et al. 2016).
REDEFINING THE EMT PROGRAM
Given the currently rapid progress of EMT research
and the extensive literature on this topic that has been
produced in recent years, we would propose two guide-
lines that can be used to understand EMT programs in the
context of carcinoma progression and metastasis. First,
the EMT appears to generate cells residing in a spectrum
of states lying in multiple phenotypic states between the
highly organized epithelial state characteristic of normal
tissue architecture and the extremely mesenchymal state
resembling that of fibroblasts. A transition between any
two states within this spectrum to a more mesenchymal
state may occur under the aegis of an EMT program (Fig.
1). In the majority of instances, carcinoma cells dissem-
inate by means of tumor cell clusters; the forward march
of these clusters does not seem to require an overt tran-
sition of the bulk of the cells to a truly mesenchymal state.
Instead, the majority of cells in these clusters may have
lost certain epithelial traits, such as adherence to a base-
ment membrane and an alteration in their form of cell
polarity, whereas subpopulations of cells in these invad-
ing cell cohorts, specifically those at the leading/invasive
edges of these groups, may indeed express, at least tran-
siently, traits typically associated with EMT programs.
Accordingly, we propose that the EMT program can
actually be seen as a program presenting in many differ-
ent forms: In some forms one may observe the loss of
epithelial integrity and architecture while still retaining
the expression of certain epithelial markers (Khalil and
Friedl 2010; Clark and Vignjevic 2015), whereas in other
cases one may observe the adoption of certain mesenchy-
mal traits and markers while still retaining the expression
of epithelial traits (McCaffrey et al. 2012; Yu et al. 2013).
In yet another version of the EMT program, one may
observe a more extended expression of the program that
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involves an almost-complete loss of epithelial traits and a
gain of fibroblast-like mesenchymal traits (Bonnomet
et al. 2012).
Second, these various versions of the EMT program are
united by the fact that members of a small cohort of EMT-
TFs are expressed in cells that have begun to activate this
program, being increasingly expressed as cells advance
progressively toward a fully mesenchymal state. These
EMT-TFs include prominently Snail, Twist, Slug, and
Zeb1, among others (De Craene and Berx 2013). Depend-
ing on the nature of the EMT, these factors may be ex-
pressed at levels that are sufficient to repress the
transcription of certain genes that regulate key epithelial
features while not being sufficient to induce the expres-
sion of mesenchymal markers. Thus, CDH1, which codes
for E-cadherin, can be repressed by a number of EMT-
TFs, leading to the destabilization of adherens junctions
without the concomitant acquisition of overt mesenchy-
mal markers such as vimentin. In other cases, the coex-
pression of both epithelial and mesenchymal markers is
observed in the same cell, indicating the operation of a
different transcriptional program that maintains a hybrid
state. Nevertheless, it is clear that the version of the EMT
program induced is highly dependent on the specific
EMT-TF or combination of TFs that are expressed in a
particular context.
TARGETING THE EMT THROUGH
DIFFERENTIATION-INDUCING THERAPY
In light of the malignant traits displayed by cancer stem
cells (CSCs), an important focus of current research is the
identification and targeting of signaling pathways that
sustain residence of carcinoma cells in the CSC state.
Unfortunately, however, attempts to selectively target
carcinoma cells exhibiting exhibit stem-like properties
is thwarted by the fact that our understanding of the fac-
tors contributing to stemness—including where CSCs lie
along the epithelial-mesenchymal spectrum—remains
vague at best. Thus, in the absence of knowing which
signaling pathways are preferentially activated in the
CSCs, the choice of a particular pathway for therapeutic
targeting remains arbitrary.
A possibly more attractive therapeutic strategy for dis-
mantling the aggressive traits of CSCs that have acquired
EMT-associated traits is a strategy designed to reverse
this program by inducing a MET. The induction of an
MET in carcinoma cells would ideally involve the forced
shedding of mesenchymal traits and a reestablishment of
the epithelial cell state, integrity and architecture, which
would be accompanied by a loss of stem-like properties.
As mentioned above, it is becoming increasingly clear
that as cells undergo an EMT, they slip into a more de-
differentiated state that enhances their ability to resist
chemotherapeutic assault (Mani et al. 2008; Morel
et al. 2008; Gupta et al. 2009). Hence, the loss of stem-
ness and the process of undergoing differentiation is like-
ly to deprive these cells of traits that fuel their malignant
behavior. In fact, the induction of differentiation as a form
of therapy was first utilized for the treatment of acute
promyelocytic leukemia, where the administration of
all-trans retinoic acid was successfully used as a targeted
therapy (Warrell et al. 1993). In the case of breast and
endometrial carcinomas, the use of histone deacetylase
inhibitors (HDACis) induces their differentiation, pre-
sumably through the derepression of certain gene promot-
ers (Munster et al. 2001; Uchida et al. 2007; Xu et al.
2007). Along these lines, it appears that processes that
serve to maintain the epithelial state of cells act as potent
tumor suppressors. This is especially true for features,
such as the maintenance of cell polarity (Lee and Vasiou-
khin 2008), as well as the presence of adherens and tight
junctions (Jeanes et al. 2008; Martin and Jiang 2009)
between epithelial cells and of hemidesmosomes that
maintain interactions with the basement membrane (De
Arcangelis et al. 2016). Thus, in the case of carcinomas, it
is plausible that processes that maintain the epithelial
state are especially relevant for the prevention of malig-
nancy and EMT-induced tumor progression.
As cells undergo an EMT, a series of signaling path-
ways is activated, while a host of others are down-regu-
lated. The switch in some of these pathways, such as
TGF-b and Wnt, is initiated by paracrine signals from
the tumor-associated stroma, whereas the maintenance
of the mesenchymal state is propagated through autocrine
signals that maintain their residence in that state (Scheel
et al. 2011). Other factors such as PGE2, secreted by
mesenchymal stem cells (MSCs), are also known to in-
duce a mesenchymal/CSC state by creating a favorable
niche (Li et al. 2012). NF-kB signaling activated by in-
flammatory cytokines present in the tumor microenviron-
ment also triggers the activation of NOTCH signaling,
which allows expansion of the CSC pool in basal-like
breast cancers (Yamamoto et al. 2013). Consequently, it
seems that disruption of these paracrine and autocrine
signaling axes that maintain residence of tumor cells in
a more mesenchymal/stem-like state can force them into
a more differentiated epithelial state that would render
them more susceptible to conventional therapy. Impor-
tantly, such a treatment strategy would restore some of the
key traits of epithelial cells, such as the cell–cell junc-
tions that form the foundation of epithelial tissue integrity
and morphology.
We recently reported that the elevation of 30,50-cyclic
adenosine monophosphate (cAMP) levels in certain
breast cancer cells can, through the activation of protein
kinase A (PKA), induce an MET by enforcing a gene
expression program reminiscent of cells that normally
exhibit a fully epithelial identity, rendering these cells
more susceptible to treatment with conventional chemo-
therapeutic drugs (Pattabiraman et al. 2016). Activation
of such a pathway, which serves to induce and perpetuate
residence of cells in an epithelial state, should ideally be
an attractive target for differentiation therapy, as it cur-
tails the malignant traits that are associated with tumor
progression. Moreover, the continued stimulation of a
pathway required for epithelial maintenance is unlikely
to have any adverse effects on the already-epithelial,
more benign compartment of carcinomas or on the nor-
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mal resident epithelia of the tissue-of-origin. A caveat of
using such anMET-induced differentiation therapy in the
case of carcinomas is the observed requirement of an
MET to complete the colonization stage of the metastasis
cascade. Consequently, the induction of an MET might
inadvertently support the process of metastatic coloniza-
tion at distant sites. Nevertheless, the potential of dif-
ferentiation therapy makes it an attractive strategy for
curtailing the malignant and stem-like properties that ac-
company the induction of an EMT in carcinomas.
CONCLUSION
Recent findings have provided more insights into the
functioning of the EMT program, the nature of its man-
ifestations, and its contribution to tumor progression and
resistance to conventional therapy. These developments
have furthered our understanding of the spectrum of phe-
notypic states orchestrated by various versions of the
EMT program and provided some evidence for a partial
EMT state favoring the CSC state of carcinoma cells.
Although the precise mixture of epithelial and mesenchy-
mal traits required for carcinoma cells to enter into a
stem-like state is still unknown, there is no longer any
doubt that the epithelial state, as characterized by cell–
cell junctions, apical–basal polarity, and adherence to
a basement membrane, is unfavorable for stemness and
tumor progression. Hence, forced entrance of carcinoma
cells that previously embarked on an EMT program into a
more epithelial state likely represents an attractive strat-
egy that can be applied to eradicate the aggressive prop-
erties of a wide range of carcinoma cells.
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